Participants 27 89 4
raloxifene treatment on bone turnover in postmenopausal women.
Participants 371 403 5
postmenopausal, osteopenic women
Participants 405 630 12
Women aged 50 to 80 years received raloxifene for 96 weeks and were then randomized to continue raloxifene (group 1, n=20) or placebo (group 2, n=20) for a further 96 weeks. A third group (group 3, n=14) received no treatment
